This is a regenerative biomedical technology, which aims to address the human chronic lung diseases that currently has no pharmaceutical approach for efficient controltherapy, such as COPDlung fibrosis. The principle is to induce the in vivo reprogramming of endogenous alveolar epithelial cells through activation of stemness factor BMI1, which potentiates the repair of injured tissues.

Ninety percent of human diseases are related to abnormal inflammation. WJM team has successfully developed a new monoclonal antibody that can inhibit a key inflammation protein. Animal experiments have accumulated more than ten disease modes, including a variety of solid tumors, fibrosis, degenerativecardiovascular diseases. This antibody is qualified as an orphan drug for the treatment of IPF. New coronary pneumonia has greatly increased the demand for pulmonary fibrosis treatment,has also become an important target for mergersacquisitions of global pharmaceutical companies.

The technology provides a new experience for remote respiratory rehabilitation care,let patients realize self-health management at home. The system has three characteristics: First, daily home pulmonary function tests to achieve early warning of disease. Second, the design of automatic feedback aperture valve provides the best positive expiratory pressure (PEP)for pulmonary rehabilitation,APP helps user to do breathing exercise. Third, electronic monitoring of inhaled medications with a two-way flow sensor module,APP helps user to guide the inhalation process.